FDA Approves NURTEC ODT for Rare Pediatric Disease, Redeeming Priority Review Voucher

Summary

The FDA has approved NURTEC ODT (rimegepant), a rare pediatric disease product, redeeming a priority review voucher. The approval was announced in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Food and Drug Administration Safety and Innovation Act (FDASIA).